HELP Company Profile and Key Details

HELP has shown sold momentum, gaining 4.07% over the past week and 27.36% over the past quarter, though year-to-date performance is down -6.11%. Short-term trend indicators are mixed aligned (SMA20 16.3%, SMA50 7.43%, SMA200 10.61%). The stock’s 14-day RSI is 61.95 (firm momentum), while the ATR of 0.59 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.06% below its high and over 61.33% above its low. Average 10-day trading volume of 601.70 thousand shares is below the 3-month average of 961.01 thousand, indicating normal recent market interest.

Cybin Inc. Common Stock generated EPS of -$4.52 over the past year. Five-year average earnings growth is -232.48%. Wall Street analysts project EPS growth of 13.28% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $95.00 to $8.00. The high target offers 1858.76% upside. The low target suggests 64.95% downside. The mean target is $51.50. This offers 961.86% upside. Cybin Inc. Common Stock earnings surprise history is a consistent trend of beating forecasts. The quarter that ended February 16, 2026, missed forecasts by 30.53%. The prior quarter beat by 35.85%. Over the last six quarters, Apple has recorded several small beats. These include -27.76% in February 10, 2025.

Cybin Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.77. This means the shares are trading near this model’s fair value.

Our AI price prediction model suggests that Cybin Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.8%, with price expected at $4.52 by July 06, 2026, within a range of $4.20 to $4.86 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by September 16, 2026, with a range of $0.00 to $0.07. 1-Year Outlook: Projected loss of -89.48%, with price at $0.51 by June 22, 2027, within a range of $0.44 to $0.59.

Cybin Inc. Common Stock (NASDAQ:HELP) closed at $4.85 USD, gaining $0.18 (3.85%) from the previous close of $4.67. The stock is currently mid-range between its 52-week high and low $3.76 and $9.83. With a market capitalization of about $241.99 million, Cybin Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.70). Key stats such as the average daily volume over the past year has been around 986.96 thousand shares, in line with its 52-week average. Headquartered in Toronto, ON, Cybin Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael F. Cola, the company employs approximately 50 people and listed since September 13, 2019. Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds.

Cybin Inc. Common Stock (NASDAQ:HELP) shares are flat -6.11% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cybin Inc. Common Stock trading at a premium to the broader market with a P/E of -0.82. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $51.50, suggesting 961.86% upside. Our AI forecast model points to short-term weakness (-6.8% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-89.48% over one year), with expected trading ranges indicating moderate volatility.

Cybin Inc. Common Stock trades at a P/E ratio of -0.82, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.43 suggesting the stock is closer to book value. The P/FCF stands at -1.96, also above market averages.